Oxford BioDynamics (LON:OBD) Issues Earnings Results

Oxford BioDynamics (LON:OBD) posted its earnings results on Friday. The biotechnology company reported GBX (4.50) (($0.06)) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

Oxford BioDynamics Stock Down 8.7 %

OBD opened at GBX 0.53 ($0.01) on Friday. Oxford BioDynamics has a fifty-two week low of GBX 0.45 ($0.01) and a fifty-two week high of GBX 15 ($0.19). The company has a debt-to-equity ratio of 370.22, a quick ratio of 2.80 and a current ratio of 0.68. The company has a fifty day moving average of GBX 0.77 and a two-hundred day moving average of GBX 2.19. The stock has a market capitalization of £9.90 million, a price-to-earnings ratio of -0.09 and a beta of 0.42.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.